Objective: To describe the hospital medical resources used in adults hospitalized with respiratory syncytial virus infection and to evaluate the association of comorbidities with resource utilization and clinical outcomes. Design: A retrospective cohort study was conducted using the electronic healthcare database of Hospital Alemán, Buenos Aires, Argentina. It included hospitalized patients aged 18 years or older who had a positive test for respiratory syncytial virus between September 2010 and December 2023. Data were analyzed using standard statistical methods following STROBE guidelines. Results: Among 72 hospitalized adults with confirmed respiratory syncytial virus infection, the mean length of hospital stay was 12.18 days (SD 12.91), and 27 (37.5%) patients required intensive care unit admission. Healthcare resource utilization was substantial, with 26% needing non-invasive ventilation and 11% requiring mechanical ventilation. Antibiotics (75%) and corticosteroids (68.05%) were commonly used, likely reflecting the severity of clinical presentation or the potential for bacterial coinfection. Cardiovascular comorbidities were significantly associated with severe disease outcomes and intensive care unit admission (OR 3.53, 95% CI: 1.00–12.54). Comparative analysis with 226 influenza patients showed respiratory syncytial virus patients had longer hospital stays and higher intensive care unit admission rates. Conclusions: Respiratory syncytial virus infection in adults resulted in substantial medical resource utilization and significant intensive care unit admission and ventilation support requirements. Cardiovascular comorbidities might be associated with increased severity and intensive care unit admissions. The high rate of antibiotic use is noteworthy and warrants further investigation to understand prescribing patterns and optimize antimicrobial stewardship. Compared to influenza, respiratory syncytial virus appears to be associated with longer hospital stays and higher intensive care unit admissions, highlighting the need for tailored management strategies for respiratory syncytial virus in adult populations. Further research should focus on optimizing treatment protocols and preventive measures for respiratory syncytial virus.
Objective: To describe the hospital medical resources used in adults hospitalized with respiratory syncytial virus infection and to evaluate the association of comorbidities with resource utilization and clinical outcomes. Design: A retrospective cohort study was conducted using the electronic healthcare database of Hospital Alemán, Buenos Aires, Argentina. It included hospitalized patients aged 18 years or older who had a positive test for respiratory syncytial virus between September 2010 and December 2023. Data were analyzed using standard statistical methods following STROBE guidelines. Results: Among 72 hospitalized adults with confirmed respiratory syncytial virus infection, the mean length of hospital stay was 12.18 days (SD 12.91), and 27 (37.5%) patients required intensive care unit admission. Healthcare resource utilization was substantial, with 26% needing non-invasive ventilation and 11% requiring mechanical ventilation. Additionally, 75% received antibiotics, and 68.05% were treated with corticosteroids. Cardiovascular comorbidities were significantly associated with severe disease outcomes and intensive care unit admission (OR 3.53, 95% CI: 1.00-12.54). Comparative analysis with 226 influenza patients showed respiratory syncytial virus patients had longer hospital stays and higher intensive care unit admission rates. Conclusions: Respiratory syncytial virus infection in adults resulted in substantial medical resource utilization and significant intensive care unit admission and ventilation support requirements. Cardiovascular comorbidities are associated with increased severity and intensive care unit admission admissions. Compared to influenza, respiratory syncytial virus leads to longer hospital stays and higher intensive care unit admissions, highlighting the need for tailored management strategies for respiratory syncytial virus in adult populations. Further research should focus on optimizing treatment protocols and preventive measures for respiratory syncytial virus.
Background/Objectives: Influenza remains a primary cause of severe illness and death in adults over 60. In this group, immunosenescence and existing health conditions make infections more dangerous and traditional vaccines less effective. The MF59-adjuvanted vaccine was specifically designed to overcome these limitations by enhancing the body’s immune activation and antigen presentation. While the vaccine shows clear benefits, some recent concerns regarding vaccine safety have been raised without supporting scientific evidence. Therefore, this systematic review focuses on providing a comprehensive evaluation of its safety outcomes compared to standard vaccines. Methods: Following the PRISMA guidelines, a systematic review and meta-analysis were conducted; two researchers independently assessed the eligibility of the studies, and the risk of bias was assessed using RoB2 and ROBINS tools for randomized clinical trials and observational studies, respectively. Pooled risk estimates were calculated using a random-effects model. Results: Ten RCTs and three non-RCTs meeting the inclusion criteria were included. No significant differences were found for severe systemic outcomes: Guillain–Barré syndrome (RR 1.01, 95% CI 0.64–1.80) and encephalitis (RR 1.23, 95% CI 0.85–1.78). For other systemic adverse effects, there were no significant differences between adjuvanted and non-adjuvanted vaccines; only myalgia showed a small but significant increase with adjuvanted vaccines (RR 1.35, 95% CI 1.02–1.78) compared with non-adjuvanted vaccines. Conclusions: MF59-adjuvanted influenza vaccines have a favorable and well-characterized safety profile in adults aged 60 years and older. Adverse events are predominantly mild and transient, with no evidence of increased risk of serious or immune-mediated outcomes compared with non-adjuvanted vaccines.